Living Cell loss

Living Cell Technologies, the ASXlisted biotech company with New Zealand-based operations, reported a wider loss in the six months to December 31 on increased research and development. The company said its consolidated operating loss after tax was A$2.1 million ($2.2m) versus a loss of A$1.4m in the same period a year earlier. The main reason was increased costs incurred during the clinical trial of Living Cell’s NTCELL product to treat Parkinson’s disease, as well as the cost of security the supply and manufacture of NTCELL, the company said.